Application of Propofol Target Controlled Infusion Combined with Etomidate in Painless Gastrointestinal Endoscopy: A Prospective, Randomized, Controlled Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044708

Enrollment

Unknown

Registered

2021-03-26

Start date

2018-08-01

Completion date

Unknown

Last updated

2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal disease

Interventions

propofol:propofol TCI

0.1EP group:propofol TCI plus 0.1mg/kg etomidate

0.15EP group:propofol TCI plus 0.15mg/kg etomidate

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Scheduled for painless gastrointestinal endoscopy; (2) Aged 18-75 years; (3) With American Society of Anesthesiologists (ASA) physical status I to III; (4) With Mallampati classification I or II.

Exclusion criteria

Exclusion criteria: (1) With circulation dysfunction,liver dysfunction,kidney dysfunction and other important organ dysfunction; (2) Allergic to propofol or fat emulsion; (3) A history of drug abuse; (4) With acute upper respiratory infection; (5) With Obstructive sleep apnea hypopnea syndrome or body mass index, BMI >= 28kg/m2; (6) With adrenal insufficiency.

Design outcomes

Primary

Measure	Time frame
Blood pressure;Heart rate;Oxygenation;Incidence of hypotension;Incidence of bradycardia;concentration of propofol TCI when patient sleep;	—

Secondary

Measure	Time frame
recovery time;Induction time;Incidence of injection pain;Incidence of postoperative nausea and vomiting; Patients' and physicians' satisfaction of sedation;	—

Countries

China

Contacts

Public ContactLuo Huirong

Fujian Medical University Union Hospital

470797962@qq.com+86 17706918361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026